ERß expression predicts breast cancer risk in hyperplasia

Bookmark and Share
Published: 14 Jul 2016
Views: 2025
Dr Tina Hieken - Mayo Clinic, Rochester, USA

Dr Hieken speaks with ecancertv at EACR 2016 about the significance of a potential biomarker for breast cancer in hyperplasia patients.

She describes how the subpopulation of patients, those with atypical hyperplasia of the breast and high levels of ERß, can act on this information with further breast cancer treatment, and the choice faced in risk reduction.

Dr Hieken also summarises the interests and technologies being investigated in her lab, and the future of breast cancer prevention.